發(fā)布時間：2018-05-21 19:06

  本文選題：甲氨蝶呤 + 克羅恩病　； 參考：《中國藥房》2017年06期

【摘要】：目的:為進(jìn)一步合理使用甲氨蝶呤(MTX)治療克羅恩病(CD)提供參考。方法:通過查閱國內(nèi)外文獻(xiàn),就MTX的作用機(jī)制、臨床療效及不良反應(yīng)相關(guān)研究進(jìn)行歸納和綜述。結(jié)果:MTX可能通過抑制T細(xì)胞的增殖,下調(diào)炎癥介質(zhì)表達(dá),抑制炎癥反應(yīng)而發(fā)揮作用;MTX用于CD活動期和緩解期的療效均顯著,但劑量和療程的選擇有所不同;并且,其長期使用安全性較高。結(jié)論:甲氨蝶呤對于激素依賴/無效、對嘌呤類似物抵抗或生物制劑治療失敗的CD患者(包括兒童)而言是一種不錯的選擇,但應(yīng)進(jìn)一步探索其合適的使用劑量、給藥途徑等,并加強(qiáng)其安全性評價。
[Abstract]:Objective: to provide reference for the rational use of methotrexate (MTX) in the treatment of Crohn's disease. Methods: the mechanism, clinical efficacy and adverse reactions of MTX were summarized and summarized by consulting the literature at home and abroad. Results it was possible that the effects of TX on CD activity and remission were significant by inhibiting the proliferation of T cells, down-regulating the expression of inflammatory mediators and inhibiting inflammatory response, but the dose and course of treatment were different. Its long-term use safety is high. Conclusion: methotrexate is a good choice for CD patients (including children) who are dependent on hormone, resistant to purine analogue or failed in biological treatment, but we should further explore the appropriate dosage and route of administration of methotrexate. And strengthen its safety evaluation.
【作者單位】： 上海交通大學(xué)醫(yī)學(xué)院附屬瑞金醫(yī)院藥劑科;
【基金】：上海市臨床藥學(xué)重點(diǎn)�？平ㄔO(shè)項(xiàng)目(No.滬衛(wèi)計藥政[2016]7、8號)
【分類號】：R574.62

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 張昆鵬;甲氨蝶呤在日本導(dǎo)致134例患者死亡[J];基層醫(yī)學(xué)論壇;2005年03期

2 賴毓冕;葉明;張秋實(shí);黃薇;;甲氨蝶呤全身用藥成功治療剖宮產(chǎn)子宮瘢痕處妊娠[J];中華實(shí)用診斷與治療雜志;2009年03期

3 王敏;;甲氨蝶呤治療未破裂型異位妊娠分析[J];臨床合理用藥雜志;2009年03期

4 朱光華;周，

本文編號：1920388